ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: March 2024
|
Report Code: QYRE-Auto-5U12923
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Research Report 2023
BUY CHAPTERS

Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-5U12923
Report
March 2024
Pages:135
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix Inc
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI

Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market Size

The global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications was estimated to be worth US$ 21390 million in 2023 and is forecast to a readjusted size of US$ 29810 million by 2030 with a CAGR of 4.8% during the forecast period 2024-2030

Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market

Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market

A biomarker is, according to the US National Institutes of Health, “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention.”
Biomarkers make take the form of cellular characteristics, metabolites (e.g. sugars, lipids and hormones), molecular variations, or physical features (e.g., clinical symptoms) and are assessed accordingly, via measurement, annotation, documents, and images.
Increasingly, the discovery of novel biomarkers is closely associated with the advances in molecular biology techniques that can be accessed through analysis of DNA, RNA or proteins.
We can discriminate four main types of molecular biomarkers:
• Genomic biomarkers: Based on the analysis of DNA (deoxyribonucleic acid) profiles, especially the analysis of SNPs (single nucleotide polymorphisms), i.e. identification of punctual variations in genomic DNA.
• Transcriptomic biomarkers: Base on the analysis of RNA expression profiles.
• Proteomic biomarkers: Base on the analysis of the protein profiles.
• Metabolomic biomarkers: Base on the analysis of metabolites (metabolites are the intermediates and products of metabolism).
Commercializing biomarkers is the path that a biomarker could be used in therapeutic or diagnostic. In this report mainly covers consumables, services, software of this market.
The major players in global Commercializing Biomarkers in Therapeutic and Diagnostic Applications market include Roche, Dako (Agilent Technologies), Affymetrix, etc. The top 3 players occupy about 10% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Consumables is the main type, with a share about 60%. The main applications include Oncology, Cardiology, Neurology, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Commercializing Biomarkers in Therapeutic and Diagnostic Applications, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications by region & country, by Type, and by Application.
The Commercializing Biomarkers in Therapeutic and Diagnostic Applications market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Commercializing Biomarkers in Therapeutic and Diagnostic Applications.
Market Segmentation

Scope of Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market Report

Report Metric Details
Report Name Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market
Forecasted market size in 2030 US$ 29810 million
CAGR 4.8%
Forecasted years 2024 - 2030
Segment by Type:
  • Consumables
  • Services
  • Software
Segment by Application
  • Oncology
  • Cardiology
  • Neurology
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia, ALMAC, Arrayit, Biocartic, BG Medicine, KEGG EXPRESSION Database, Thermo Fisher, BGI
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Commercializing Biomarkers in Therapeutic and Diagnostic Applications manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Revenue of Commercializing Biomarkers in Therapeutic and Diagnostic Applications in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

What is the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market size in 2030?

Ans: The Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market size in 2030 will be US$ 29810 million.

What is the market share of major companies in Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market?

Ans: The top 3 players occupy about 10% shares of the global market.

What is the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market share by type?

Ans: Consumables is the main type, with a share about 60%.

Who are the main players in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market report?

Ans: The main players in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market are Roche, Dako (Agilent Technologies), Merck, BD, Abbott, Genesys Biolabs (20/20GeneSystems), Affymetrix, Agendia, ALMAC, Arrayit, Biocartic, BG Medicine, KEGG EXPRESSION Database, Thermo Fisher, BGI

What are the Application segmentation covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market report?

Ans: The Applications covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market report are Oncology, Cardiology, Neurology, Other

What are the Type segmentation covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market report?

Ans: The Types covered in the Commercializing Biomarkers in Therapeutic and Diagnostic Applications - Market report are Consumables, Services, Software

1 Market Overview
1.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Introduction
1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Size Forecast
1.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends & Drivers
1.3.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industry Trends
1.3.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers & Opportunity
1.3.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
1.3.4 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players Revenue Ranking (2023)
2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2019-2024)
2.3 Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Base Distribution and Headquarters
2.4 Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Offered
2.5 Key Companies Time to Begin Mass Production of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
2.6 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Competitive Analysis
2.6.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Consumables
3.1.2 Services
3.1.3 Software
3.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type
3.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Type (2019-2030)
3.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Oncology
4.1.2 Cardiology
4.1.3 Neurology
4.1.4 Other
4.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application
4.2.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Application (2019-2030)
4.2.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region
5.1.1 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2019-2024)
5.1.3 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2025-2030)
5.1.4 Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.2.2 North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.3.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.4.2 Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.5.2 South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
5.6.2 Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value
6.3 United States
6.3.1 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.3.2 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.4.2 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.5.2 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.5.3 China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.6.2 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.7.2 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.8.2 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019-2030
6.9.2 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
6.9.3 India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Roche
7.1.1 Roche Profile
7.1.2 Roche Main Business
7.1.3 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.1.4 Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.1.5 Roche Recent Developments
7.2 Dako (Agilent Technologies)
7.2.1 Dako (Agilent Technologies) Profile
7.2.2 Dako (Agilent Technologies) Main Business
7.2.3 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.2.4 Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.2.5 Dako (Agilent Technologies) Recent Developments
7.3 Merck
7.3.1 Merck Profile
7.3.2 Merck Main Business
7.3.3 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.3.4 Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.3.5 BD Recent Developments
7.4 BD
7.4.1 BD Profile
7.4.2 BD Main Business
7.4.3 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.4.4 BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.4.5 BD Recent Developments
7.5 Abbott
7.5.1 Abbott Profile
7.5.2 Abbott Main Business
7.5.3 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.5.4 Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.5.5 Abbott Recent Developments
7.6 Genesys Biolabs (20/20GeneSystems)
7.6.1 Genesys Biolabs (20/20GeneSystems) Profile
7.6.2 Genesys Biolabs (20/20GeneSystems) Main Business
7.6.3 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.6.4 Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.6.5 Genesys Biolabs (20/20GeneSystems) Recent Developments
7.7 Affymetrix
7.7.1 Affymetrix Profile
7.7.2 Affymetrix Main Business
7.7.3 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.7.4 Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.7.5 Affymetrix Recent Developments
7.8 Agendia
7.8.1 Agendia Profile
7.8.2 Agendia Main Business
7.8.3 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.8.4 Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.8.5 Agendia Recent Developments
7.9 ALMAC
7.9.1 ALMAC Profile
7.9.2 ALMAC Main Business
7.9.3 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.9.4 ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.9.5 ALMAC Recent Developments
7.10 Arrayit
7.10.1 Arrayit Profile
7.10.2 Arrayit Main Business
7.10.3 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.10.4 Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.10.5 Arrayit Recent Developments
7.11 Biocartic
7.11.1 Biocartic Profile
7.11.2 Biocartic Main Business
7.11.3 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.11.4 Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.11.5 Biocartic Recent Developments
7.12 BG Medicine
7.12.1 BG Medicine Profile
7.12.2 BG Medicine Main Business
7.12.3 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.12.4 BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.12.5 BG Medicine Recent Developments
7.13 KEGG EXPRESSION Database
7.13.1 KEGG EXPRESSION Database Profile
7.13.2 KEGG EXPRESSION Database Main Business
7.13.3 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.13.4 KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.13.5 KEGG EXPRESSION Database Recent Developments
7.14 Thermo Fisher
7.14.1 Thermo Fisher Profile
7.14.2 Thermo Fisher Main Business
7.14.3 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.14.4 Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.14.5 Thermo Fisher Recent Developments
7.15 BGI
7.15.1 BGI Profile
7.15.2 BGI Main Business
7.15.3 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
7.15.4 BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue (US$ Million) & (2019-2024)
7.15.5 BGI Recent Developments
8 Industry Chain Analysis
8.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain
8.2 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Model
8.5.2 Sales Channel
8.5.3 Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Roche
Dako (Agilent Technologies)
Merck
BD
Abbott
Genesys Biolabs (20/20GeneSystems)
Affymetrix Inc
Agendia
ALMAC
Arrayit
Biocartic
BG Medicine
KEGG EXPRESSION Database
Thermo Fisher
BGI
List of Tables
    Table 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Trends
    Table 2. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Drivers & Opportunity
    Table 3. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Challenges
    Table 4. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Restraints
    Table 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Type
    Table 9. Key Companies Time to Begin Mass Production of Commercializing Biomarkers in Therapeutic and Diagnostic Applications
    Table 10. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Commercializing Biomarkers in Therapeutic and Diagnostic Applications as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2019-2024) & (%)
    Table 27. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2025-2030) & (US$ Million)
    Table 31. Roche Basic Information List
    Table 32. Roche Description and Business Overview
    Table 33. Roche Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Roche (2019-2024)
    Table 35. Roche Recent Developments
    Table 36. Dako (Agilent Technologies) Basic Information List
    Table 37. Dako (Agilent Technologies) Description and Business Overview
    Table 38. Dako (Agilent Technologies) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Dako (Agilent Technologies) (2019-2024)
    Table 40. Dako (Agilent Technologies) Recent Developments
    Table 41. Merck Basic Information List
    Table 42. Merck Description and Business Overview
    Table 43. Merck Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Merck (2019-2024)
    Table 45. Merck Recent Developments
    Table 46. BD Basic Information List
    Table 47. BD Description and Business Overview
    Table 48. BD Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of BD (2019-2024)
    Table 50. BD Recent Developments
    Table 51. Abbott Basic Information List
    Table 52. Abbott Description and Business Overview
    Table 53. Abbott Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Abbott (2019-2024)
    Table 55. Abbott Recent Developments
    Table 56. Genesys Biolabs (20/20GeneSystems) Basic Information List
    Table 57. Genesys Biolabs (20/20GeneSystems) Description and Business Overview
    Table 58. Genesys Biolabs (20/20GeneSystems) Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Genesys Biolabs (20/20GeneSystems) (2019-2024)
    Table 60. Genesys Biolabs (20/20GeneSystems) Recent Developments
    Table 61. Affymetrix Basic Information List
    Table 62. Affymetrix Description and Business Overview
    Table 63. Affymetrix Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Affymetrix (2019-2024)
    Table 65. Affymetrix Recent Developments
    Table 66. Agendia Basic Information List
    Table 67. Agendia Description and Business Overview
    Table 68. Agendia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Agendia (2019-2024)
    Table 70. Agendia Recent Developments
    Table 71. ALMAC Basic Information List
    Table 72. ALMAC Description and Business Overview
    Table 73. ALMAC Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of ALMAC (2019-2024)
    Table 75. ALMAC Recent Developments
    Table 76. Arrayit Basic Information List
    Table 77. Arrayit Description and Business Overview
    Table 78. Arrayit Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Arrayit (2019-2024)
    Table 80. Arrayit Recent Developments
    Table 81. Biocartic Basic Information List
    Table 82. Biocartic Description and Business Overview
    Table 83. Biocartic Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Biocartic (2019-2024)
    Table 85. Biocartic Recent Developments
    Table 86. BG Medicine Basic Information List
    Table 87. BG Medicine Description and Business Overview
    Table 88. BG Medicine Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 89. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of BG Medicine (2019-2024)
    Table 90. BG Medicine Recent Developments
    Table 91. KEGG EXPRESSION Database Basic Information List
    Table 92. KEGG EXPRESSION Database Description and Business Overview
    Table 93. KEGG EXPRESSION Database Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 94. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of KEGG EXPRESSION Database (2019-2024)
    Table 95. KEGG EXPRESSION Database Recent Developments
    Table 96. Thermo Fisher Basic Information List
    Table 97. Thermo Fisher Description and Business Overview
    Table 98. Thermo Fisher Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 99. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of Thermo Fisher (2019-2024)
    Table 100. Thermo Fisher Recent Developments
    Table 101. BGI Basic Information List
    Table 102. BGI Description and Business Overview
    Table 103. BGI Commercializing Biomarkers in Therapeutic and Diagnostic Applications Products, Services and Solutions
    Table 104. Revenue (US$ Million) in Commercializing Biomarkers in Therapeutic and Diagnostic Applications Business of BGI (2019-2024)
    Table 105. BGI Recent Developments
    Table 106. Key Raw Materials Lists
    Table 107. Raw Materials Key Suppliers Lists
    Table 108. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Downstream Customers
    Table 109. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Distributors List
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
    Table 113. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Product Picture
    Figure 2. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 4. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Report Years Considered
    Figure 5. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Commercializing Biomarkers in Therapeutic and Diagnostic Applications Revenue in 2023
    Figure 7. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Consumables Picture
    Figure 9. Services Picture
    Figure 10. Software Picture
    Figure 11. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 12. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value Market Share by Type, 2023 & 2030
    Figure 13. Product Picture of Oncology
    Figure 14. Product Picture of Cardiology
    Figure 15. Product Picture of Neurology
    Figure 16. Product Picture of Other
    Figure 17. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value Market Share by Application, 2023 & 2030
    Figure 19. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 20. North America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
    Figure 21. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 22. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
    Figure 23. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 24. Asia Pacific Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
    Figure 25. South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 26. South America Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
    Figure 27. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (2019-2030) & (US$ Million)
    Figure 28. Middle East & Africa Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Country (%), 2023 VS 2030
    Figure 29. Key Countries/Regions Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value (%), (2019-2030)
    Figure 30. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 31. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 32. United States Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 33. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 34. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 35. Europe Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 36. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 37. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 38. China Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 39. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 40. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 41. Japan Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 42. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 43. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 44. South Korea Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 45. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 46. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 47. Southeast Asia Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 48. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value, (2019-2030) & (US$ Million)
    Figure 49. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Type (%), 2023 VS 2030
    Figure 50. India Commercializing Biomarkers in Therapeutic and Diagnostic Applications Sales Value by Application (%), 2023 VS 2030
    Figure 51. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Industrial Chain
    Figure 52. Commercializing Biomarkers in Therapeutic and Diagnostic Applications Manufacturing Cost Structure
    Figure 53. Channels of Distribution (Direct Sales, and Distribution)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Novocure

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Veterinary Drugs Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-31X6782
Fri May 17 00:00:00 UTC 2024

Add to Cart

Global Pharmaceutical Coating Devcie Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-7E13021
Fri May 17 00:00:00 UTC 2024

Add to Cart

Global Animal Antibacterial Peptide Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-20G6893
Fri May 17 00:00:00 UTC 2024

Add to Cart

Global Medical Biological Indicator Incubator Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-34Y12560
Fri May 17 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions